Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

26
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
07/17/2014 07/18/2014 07/21/2014 07/22/2014 07/23/2014 Date
67.5(c) 67(c) 66.07(c) 67.44(c) 68.6(c) Last
97 768 56 133 44 332 52 772 41 522 Volume
-2.27% -0.74% -1.39% +2.07% +1.72% Change
More quotes
Company
MorphoSys AG is engaged in the development of antibodies for therapeutic, diagnostic, and research applications. It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec. The Partnered Discovery segment involves technologies for the generation of... 
Surperformance© rating of MorphoSys AG
Trading Rating : Investor Rating :
More about the company
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 61,2 M
EBIT 2014 -14,0 M
Net income 2014 -10,6 M
Finance 2014 194 M
Yield 2014 -
Sales 2015 72,7 M
EBIT 2015 -6,64 M
Net income 2015 -10,3 M
Finance 2015 182 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 26,4x
EV / Sales 2015 22,4x
Capitalization 1 809 M
More Financials
Latest news on MORPHOSYS AG
1d ago GALAPAGOS : MorphoSys and Galapagos Advance Joint Antibody Program in Inflammato..
3d ago MORPHOSYS : to Host Q2 2014 Conference Call on 28 July 2014
3d ago MORPHOSYS : Receives Additional Patents on Novel Antibody Platform Ylanthia in t..
6d ago MORPHOSYS : Receives Additional Patents on Novel Antibody Platform Ylanthia in t..
06/12 MORPHOSYS : and Merck Serono Enter Strategic Immuno-Oncology Collaboration
06/04 MORPHOSYS : Patent Issued for Melibiose Operon Expression System
06/02 MORPHOSYS : to Present at Four Investor Conferences in June
05/27 MORPHOSYS : Annual General Meeting of MorphoSys AG Approves All Proposals of the..
05/23 MORPHOSYS : Annual General Meeting of MorphoSys AG Approves All Proposals of the..
05/20 MorphoSys's MOR208 Program to Receive Orphan Drug Designation from FDA and EM..
05/06 MORPHOSYS : to Present at Two Upcoming Investor Conferences
04/29 MORPHOSYS : Reports Results for the First Quarter of 2014
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
MorphoSys AG : Income Statement Evolution
More Financials
EPS Revisions
MorphoSys AG : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF